本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Swift inclusion of innovative liver tumor treatment technology, lowers barriers for Hongkongers to access advanced medical services HONG KONG, March 14, 2025 /PRNewswire/ -- Bowtie, Hong Kong's first virtual insurer[1], collaborates with Gleneagles Hospital Hong Kong (Gleneagles), Asia's first private hospital to offer Histotripsy treatment, to enhance the "Bowtie & Gleneagles Hospital Wellness Package"[2]. Through the swift integration of this innovative liver tumor treatment technology[3] into Bowtie's VHIS rider under Bowtie VHIS Flexi Plan and Bowtie Pink, the collaboration aims to reduce barriers for Hongkongers to access advanced medical services, enabling more patients to benefit from Histotripsy treatment. This upgrade takes effect immediately. Existing policyholders of Bowtie's VHIS plans who have opted for the "Gleneagles Hospital Wellness Package" are now eligible for full reimbursement for Histotripsy treatment[4] and can enjoy the service of "Cashless Settlement Application Waiver[5]. This VHIS rider also covers 249 designated "all-inclusive fixed price medical packages" provided by Gleneagles. Patients simply need to indicate they hold this wellness package upon seeking medical treatment at Gleneagles. Bowtie and Gleneagles will handle the service application process, eliminating paperwork and allowing patients to focus entirely on their recovery. Liver cancer is one of the most pressing issues in Hong Kong, ranking as the fifth most common cancer with 1,612 new cases in 2022 and the third leading cause of cancer deaths with 1,408 deaths in 2023[6]. While 5.6% of Hongkongers carry chronic hepatitis B—one of the key risk factors for liver cancer—advanced treatments are vital for local patients[7]. Unlike conventional surgery or radiation therapy, Histotripsy employs high-intensity ultrasound waves to destroy and liquefy targeted tumor cells, offering patients an additional, precise option for tumor elimination. Approved by the U.S. Food and Drug Administration in 2023 for the treatment of liver cancer, this technology has gained increasing recognition worldwide. In Asia, following its introduction to Hong Kong last year, Gleneagles will commence its Histotripsy treatment service towards the end of March. This partnership with Bowtie to enhance the VHIS rider not only lowers the threshold for Hongkongers to access cutting-edge medical services but also underscores Hong Kong's leadership in medical innovation within the private healthcare landscape. Mr. Fred Ngan, Co-Founder of Bowtie, stated, "As a home-grown local insurer, Bowtie is committed to unlocking private healthcare services for Hongkongers. We believe our role goes beyond simply financing private care, and we aim to drive innovation and empower patients with greater opportunities to access advanced medical technologies like Histotripsy, making them both accessible and affordable." Mr. Fred Ngan added, "Recent data reveals that around 20% of eligible VHIS customers have the 'Medical Insurance + Wellness' packages, indicating the strong demand and confidence in private medical services. We are delighted to have partnered with Gleneagles, an like-minded and forward-thinking organization, to bring this collaboration to life. " Dr. Kenneth Tsang, Chief Executive Officer of Gleneagles Hospital Hong Kong and Regional Chief Executive Officer of IHH Healthcare North Asia, stated, "We are excited to offer this transformative Histotripsy treatment for liver cancer with our full-trained medical team, providing an additional treatment option and a new hope for patients. We believe that our collaboration with Bowtie will help further enhance patients' access to cutting-edge healthcare solutions while providing them with extra peace of mind." As part of this partnership, Bowtie and Gleneagles are dedicated to providing quality healthcare education to raise awareness about Histotripsy and promote its adoption, ensuring more liver cancer patients can benefit from this groundbreaking technology. More information about the Histotripsy technology and liver cancer treatment package are available on the website of Gleneagles Hospital Hong Kong. About Bowtie The Bowtie Life Insurance Company Limited is an authorised life insurance company and Hong Kong's first virtual insurer. Its vision is to bridge the medical protection gap and transform the way people access healthcare in Hong Kong. By combining modern technology and medical expertise, Bowtie offers a commission-free and convenient online platform for customers to quote, apply, and claim for medical insurance plans anytime, anywhere. Bowtie is backed by Sun Life Financial, Mitsui & Co, and supported by leading international investors. Currently, Bowtie has raised more than HK$680 million and provided over HK$100 billion of insured value to families. Stay up to date at https://www.bowtie.com.hk/en/. About Gleneagles Hospital Hong Kong Located at Wong Chuk Hang on Hong Kong Island South, Gleneagles Hospital Hong Kong (Gleneagles) is a multi-specialty private hospital, providing cutting-edge medical technologies and a comprehensive range of clinical services spanning more than 35 specialties and subspecialties. As Hong Kong's top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research. Gleneagles is a joint venture between IHH Healthcare and CTF Services Limited, with The University of Hong Kong as its exclusive clinical partner. Gleneagles Hospital Hong Kong is part of IHH Healthcare, one of the world's largest healthcare providers. With its full spectrum of integrated services, dedicated people, reach and scale, and commitment to quality and safety, IHH aspires to be the world's most trusted healthcare services network, united by a single purpose: to touch lives and transform care. More information on Gleneagles Hospital Hong Kong can be found at https://www.gleneagles.hk/. [1] Bowtie is the first company authorised by Hong Kong's Insurance Authority under its Fast Track Pilot Scheme [2] "Gleneagles Hospital Wellness Package" is not a certified plan under the Voluntary Health Insurance Scheme, and the respective premium is not tax deductible [3] Histosonics: https://histosonics.com/news/fda-awards-histosonics-clearance-of-its-first-of-a-kind-edison-histotripsy-system-2/ [4] The reimbursement for the "Histotripsy Treatment - Liver Cancer Treatment Package" is an ex-gratia arrangement and it is subject to the annual or lifetime benefit limit (if applicable) of the relevant VHIS plan. If any additional expenses arise during this treatment, including complications, further surgeries, or intensive care, these costs will be reimbursed according to the relevant VHIS benefit schedule. This arrangement will take effect from March 14, 2025, until further notice. [5] GHK will submit to Bowtie on your behalf the pre-approval application in respect of the Designated Medical Packages(s) for the intended surgery(ies)/ procedure(s) for the cashless settlement service, which the cashless settlement service is subject to Bowtie's approval. [6] The Hong Kong Cancer Registry: https://www3.ha.org.hk/cancereg/pdf/overview/Overview%20of%20HK%20Cancer%20Stat%202022_tc.pdf [7] Information Services Department: https://www.info.gov.hk/gia/general/202407/28/P2024072600568.htm?fontSize=1
PETALING JAYA, Malaysia, March 14, 2025 /PRNewswire/ -- Klinik Pakar Mata VISTA Eye Specialist (VISTA), a well-established name in eye care in Malaysia, continues to improve its cataract surgery services through collaborations with recognized ophthalmic technology providers such as Johnson & Johnson Surgical Vision (Johnson & Johnson) and Ziemer Ophthalmic Systems AG (Ziemer). These collaborations reaffirm VISTA's commitment to investing in innovative technology, including Artificial Intelligence (AI), to support safe and effective patient care. Cataract: A Leading Cause of Visual Impairment Cataracts remain a common cause of vision loss worldwide, affecting millions annually. According to the World Health Organization (WHO), approximately 17% of people with cataract have received access to an appropriate intervention (WHO, 2023). While this condition is often associated with aging, genetics, diabetes, or prolonged UV exposure may contribute to its development. Fortunately, cataract surgery has been shown to be safe and effective. However, individual outcomes may vary depending on pre-existing eye conditions and overall health. Patients are encouraged to consult with qualified eye specialists to determine their suitability for treatment. For more than 25 years, VISTA has been providing comprehensive ophthalmic care, attracting patients from Malaysia and beyond, including Singapore, Indonesia, and Australia. "Cataract surgery today is about precision, patient safety, and personalized care. By working with recognized partners like Johnson & Johnson and Ziemer, we can introduce advanced solutions, including AI-assisted technologies, to improve patient treatment options," said Grace Heng, Chief Growth Officer of VISTA. Advancing Cataract Surgery Through Technology VISTA integrates advanced technology into cataract surgery, including: Johnson & Johnson's VERITAS™ Vision System TECNIS PureSee™ Intraocular Lens – Patients should discuss with their doctor to determine the most suitable lens option for their needs. Ziemer Femtosecond Laser Technology "Our goal is to combine modern surgical techniques, technological advancements, and patient-centered care. However, it is important for patients to understand that results can vary depending on individual eye health and other medical conditions," added Dr. Aloysius Joseph Low, Founder and Medical Director of VISTA. The Role of Partnerships in Cataract Surgery In the evolving field of cataract surgery, partnerships with leading vision care companies play an essential role in: Providing Surgeons with Access to Modern Technology – Ensuring eye specialists have access to advanced surgical tools to support efficient and precise procedures. Enhancing Patient Safety—Modern cataract surgery techniques use minimally invasive approaches, which reduces recovery times for eligible patients. Supporting Continuous Medical Advancements – Ongoing research and innovation in ophthalmology enable continuous improvements in patient outcomes. "Advancements in eye care depend on responsible innovation and the adoption of well-researched medical technologies. At VISTA, we aim to provide evidence-based treatments that align with international ophthalmic standards," said Dr. Aloysius. Recognition in Ophthalmic Care VISTA's contributions to eye care have been acknowledged through its inclusion in Newsweek Asia's Top Private Hospitals 2025, as well as its recognition as a B Corp-certified organization for its commitment to sustainability and ethical medical practices. Guiding Patients Towards Better Vision and Quality of Life At the core of VISTA's patient care philosophy is Ikigai—a principle that promotes living with clarity and purpose. VISTA helps patients restore their vision and maintain an active lifestyle by offering advanced cataract surgery options. "While cataract surgery is widely performed, each patient's journey is unique. Our role is to provide informed guidance, safe procedures, and high standards of patient care so individuals can make the best choices for their eye health," said Grace Heng. Looking Ahead: A Future of Innovation in Eye Care VISTA remains dedicated to advancing eye care services in Malaysia by continuing investments in new technology, fostering industry collaborations, and prioritizing patient education. Patients considering cataract surgery are advised to seek professional medical consultations to determine their suitability for available treatment options. About VISTA Eye Specialist Part of Qualitas Health Group, VISTA Eye Specialist provides ophthalmic services in Malaysia. It specializes in cataract surgery, refractive solutions, and general vision care. With an emphasis on technology-driven treatments and patient safety, VISTA aims to provide comprehensive eye care services based on global medical standards. References List WHO. (2023). Vision Impairment and blindness. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment
TAIPEI, March 14, 2025 /PRNewswire/ -- Cordyceps Sunshine Biotech Holdings Co., Ltd. 【C.S Group】, in collaboration with the Chinese Herbal Fungi Industry Research and Development Association (CHFIRDA), hosted the "Pharmacological Applications of Taiwanofungus Camphoratus in the Pet Market" Seminar in Taipei. During the event, 【C.S Group】 officially announced its latest research findings, revealing that Antcin A, a purified extract from Taiwanofungus camphoratus, demonstrates potential synergistic effects with traditional steroids. The company is also exploring partnerships with premium pet food brands in China and plans to introduce exclusively supplied Taiwanofungus camphoratus extracts through its Greater China distributor, Guangdong Baoquan Agricultural Biotechnology, as part of its strategy to expand into the high-end pet food market. Accelerating Commercialization of Taiwanofungus Camphoratus-Based Pharmaceuticals Dr. Jia-Xin Huang, a leading expert in Taiwanofungus camphoratus, emphasized that developing new biopharmaceuticals traditionally requires extensive investment in animal and human trials, with no guarantee of success. However, Taiwanofungus camphoratus has already been extensively researched, providing a strong scientific foundation without needing to start from scratch. A key concern in previous discussions has been the long-term use of traditional steroids, which often leads to liver and kidney damage as a side effect. Taiwanofungus camphoratus is known for its liver- and kidney-protective properties, prompting further studies into its potential to reduce the adverse effects of steroids without compromising efficacy. To validate this hypothesis, 【C.S Group】 conducted an experiment combining its proprietary TF-15 Taiwanofungus camphoratus extract with the steroid dexamethasone (DXMS) in lung cancer cell models. The study confirmed: Genetic verification of TF-15 confirmed its authenticity 【C.S Group】as a Taiwanofungus camphoratus strain. TF-15 exhibits comparable potency to wood-cultivated Taiwanofungus camphoratus fruiting bodies. A high concentration of Antcin A was successfully extracted through a multi-stage purification process. The combination of Antcin A and dexamethasone showed potential synergistic effects in reducing and reversing cancer cell growth. Recognizing the regulatory and commercialization advantages of veterinary applications, 【C.S Group】 is prioritizing preclinical trials for pet medicine. The strategy includes: Establishing safe dosage and formulations for pets, such as oral solutions and chewable tablets. Accelerating human clinical trials by leveraging veterinary data. Expanding applications to both pet and human nutraceuticals, providing a flexible market strategy. This approach offers a balanced and strategic entry into the pharmaceutical sector, positioning Taiwanofungus camphoratus as a viable candidate for integrated pet and human health solutions. (Left) C.S Group Chief Technology Officer Vincent Liu; (Right) C.S Group Consultant Dr. Jia-Xin Huang. Pet Health Market Poised for Growth Vincent Liu, Chief Technology Officer at 【C.S Group】, highlighted the significant growth potential in China's pet market. As of 2024, China's pet population reached 124.1 million, with the pet food industry valued at $22.2 billion—including $9.8 billion in cat food and $10.3 billion in dog food. While mature markets like North America and Europe have penetration rates exceeding 90%, China's market penetration is still around 20%, signaling substantial room for growth. According to the China Feed Industry Association (CFIA), there are approximately 200 certified pet food manufacturers in China, with a total annual production capacity of 1.12 million tons. The market is shifting towards premium branding, creating opportunities for high-end functional pet foods. 【C.S Group】 is actively engaging with China's leading premium pet food brands and, through its Greater China distributor, Guangdong Baoquan Agricultural Biotechnology, plans to integrate Taiwanofungus camphoratus extracts into premium pet food formulations. Beyond pet nutrition, veterinary pharmaceuticals present another growth avenue. The global pet pharmaceutical market includes treatments for external and internal parasites, allergic dermatitis, anti-inflammatory pain relief, anti-nausea, insulin, antibiotics, and heart failure management. Given the broad-spectrum bioactivity of Taiwanofungus camphoratus, its potential therapeutic applications in pet medicine are highly promising. Leading the Market with Antcin A Mass Production Dalan Huang, President of 【C.S Group】, emphasized the importance of high-quality cultivation in ensuring premium product yields. He highlighted the company's commitment to optimizing Taiwanofungus camphoratus strain selection and mass production, enabling efficient extraction and purification of bioactive compounds for pharmaceutical applications. "The efficacy of Antcin A is well established in the industry, but the real question is: who has the capability to lead the market in large-scale extraction and production?" Huang stated. "Whoever masters the mass production of Taiwanofungus camphoratus extracts will control the next phase of the industry." While the company has ambitious goals, Huang stressed the importance of achievable milestones. Based on Dr. Jia-Xin Huang's preliminary findings, 【C.S Group】 has already made exciting progress and is optimistic that further optimization will lead to the development of the first batch of Taiwanofungus camphoratus-based veterinary pharmaceuticals. This breakthrough has the potential to accelerate commercialization and integration into the pet health industry. With scientific validation, strategic partnerships, and market positioning, 【C.S Group】 is advancing Taiwanofungus camphoratus from traditional applications to next-generation pharmaceuticals. As the global pet and human health industries continue to expand, the company is well-positioned to lead innovation in functional ingredients and biopharmaceutical applications.
MIAMI, March 13, 2025 /PRNewswire/ -- MATELASER, INC., a pioneering force in laser therapy technology, is proud to announce the launch of the X1 Performance, the portable high-energy laser therapy system, designed to meet the highest U.S. medical quality standards for pain management, sports recovery, and rehabilitation. Proudly manufactured in California, with its lightweight design (only 1160g) and unique 1064nm wavelength, MATELASER X1 Performance offers deep tissue penetration, powerful pain relief, and accelerated healing—all in a compact, highly portable device. This innovative system delivers 15W ISP (Intense Super Pulse) and 12W CW (Continuous Wave) output, providing clinic-level treatments anywhere, anytime. A New Standard in Pain Management & Rehabilitation As the demand for non-invasive, drug-free pain relief continues to rise, MATELASER X1 Performance is positioned to become an essential tool for doctors, chiropractors, physiotherapists, and sports medicine professionals. Its 1064nm wavelength sets it apart from traditional laser therapy devices that use 810nm or 980nm wavelengths, as 1064nm penetrates deeper into muscles, joints, and connective tissues, delivering faster and more effective healing. "With the X1 Performance, we are bringing advanced, high-energy laser therapy to the next level—portable, powerful, and accessible to all healthcare professionals," said Brian Kenney, VP Sales and Marketing of MATELASER, INC. "Whether you are treating chronic pain, sports injuries, or post-surgical recovery, X1 Performance provides an effective, non-pharmaceutical alternative to pain relief that supports the body's natural healing process." Designed for Mobility, Versatility, and Convenience Unlike traditional laser therapy systems that are bulky and confined to clinic use, X1 Performance is designed for maximum portability and flexibility. Weighing only 1160g, it allows doctors and therapists to provide professional-level treatment on the go. Its compact and ergonomic design makes it ideal for: Sports medicine professionals treating athletes on-site at games, training sessions, and tournaments. Chiropractors and physiotherapists looking to expand their services with home visits and mobile care. Doctors providing concierge medical treatments to high-profile clients. Families seeking a powerful at-home solution for chronic pain relief and injury recovery. Cost-Effective Alternative to High-Priced Systems Historically, high-powered laser therapy devices have been prohibitively expensive, limiting their accessibility to only large-scale clinics and hospitals. MATELASER X1 Performance disrupts this market by offering a premium high-energy laser therapy device at just $5,999. For comparison, other laser therapy systems cost over $35,000—making X1 Performance a game-changer for clinics, independent practitioners, and sports medicine professionals looking for an affordable yet high-performance solution. Testimonials from Leading Healthcare Professionals Early adopters of the X1 Performance have already seen exceptional results. Dr. David Zamikoff, President of the Florida Chiropractic Association and member of the Foundation for Peripheral Neuropathy stated: "This is the best investment I've made for my practice. My patients love the deep relief they get from the 1064nm laser, and the fact that I can take it anywhere allows me to expand my services beyond my clinic." Dr. Peter Michael, a sports medicine specialist, shared: "I've worked with numerous laser therapy devices, but the portability and power of the X1 Performance are unmatched. I can now bring high-energy treatments to athletes on-site without sacrificing effectiveness." Availability & Ordering Information The MATELASER X1 Performance is now available for order in the U.S. and globally. Clinics, chiropractors, physiotherapists, and sports medicine professionals can now access a powerful, portable laser therapy solution at a fraction of the cost of traditional systems. For more information about the X1 performance laser system, visit: www.lasertherapy.com Media Contact:info@matelasers.com About MATELASER, INC. MATELASER, INC., based in Miami, is a leading medical technology company specializing in high-energy laser therapy solutions for pain relief, rehabilitation, and sports recovery. Committed to innovation, accessibility, and quality, MATELASER delivers cutting-edge, non-invasive solutions that empower healthcare professionals and patients worldwide.
CAMBRIDGE, Mass., March 13, 2025 /PRNewswire/ -- Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a $110 million Series E financing led by a private equity fund of Value Partners Group (HKG:0806), one of Asia's largest independent asset management firms, with strong participation from industry- and technology-focused new investors, as well as continued support from global existing backers. The funds raised in this round will be directed to advance Insilico's innovative drug pipeline and AI platform developments. On one side, resources will focus on refining AI models and algorithms, alongside updates and expansions to its state-of-the-art automatic lab to further automate and streamline R&D processes. On the other side, Insilico will focus on advancing the clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment and accelerating the exploration of other independently developed and co-developed drug pipelines, driving impactful innovations in healthcare. "We are excited to partner with Insilico Medicine in its mission to transform drug discovery with AI and automation. With a proven track record and a leadership position in AI-driven drug development, Insilico is at the forefront of transforming the industry. We believe that Insilico's advancements will not only accelerate the development of life-saving therapies but also redefine the future of biopharmaceutical R&D. This partnership also marks a significant milestone for Value Partners' private equity strategy and our vision of investing in disruptive innovations that have the potential to reshape industries," said Dr. Chuen Yan Leung, Partner (Healthcare Investments). "We are thrilled to announce our $110 million Series E financing—a key milestone that reflects our unwavering commitment to transforming healthcare and the strong confidence of our investors. This round, led by Value Partners and anchored by industry-focused investors, was heavily oversubscribed, drawing exceptional interest from prominent investors," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "The funds raised will accelerate the advancement of our drug pipeline and AI platform, further solidifying Insilico's leadership in this rapidly evolving sector. We remain dedicated to our mission of extending productive longevity to people and are proud to be at the forefront of innovation in healthcare." Since its previous financing round, Insilico has achieved substantial progress in both the development of AI platform and drug discovery pipeline and has showcased the ability of its proprietary AI-driven platform to significantly reduce costs and enhance efficiency in the early stages of drug discovery. As its announced key benchmarks for internal preclinical candidate (PCC) programs show: By integrating advanced AI and automation technologies, Insilico has reduced the average time to PCC nomination to just 12-18 months compared to traditional drug discovery methods (typically require 2.5-4 years) , while enabling the synthesis and testing of only 60-200 molecules per program. Pharma.AI, the proprietary platform developed by Insilico, undergoes major updates twice a year to maintain its technological edge. Built around generative AI and continuously integrating cutting-edge technologies, Pharma.AI provides a comprehensive solution spanning biology, generative chemistry, clinical medicine, and scientific research. As the technology evolves, Insilico has further enhanced Pharma.AI by introducing innovative engines powered by large language models (LLMs), including Nach01, a multimodal foundation model for natural and chemical languages, and Dora, a multi-agent generative research assistant. Recently, Insilico deployed the first bipedal humanoid AI Scientist within Life Star1, its fully robotic lab connected to Pharma.AI, designed to further optimize and automate research workflows. To date, Insilico has rapidly built a wholly-owned drug discovery portfolio of 30 assets driven by its advanced Pharma.AI platform, with 10 of these assets receiving IND clearance. Among them, the most advanced candidate, Rentosertib (formerly known as ISM001-055), developed for treating idiopathic pulmonary fibrosis (IPF), has progressed through multiple clinical studies with encouraging results. In a completed Phase IIa clinical trial, Rentosertib demonstrated favorable safety and tolerability across all dose levels, along with dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage. In addition, Insilico has established a sustainable revenue stream through its business model centered on out-licensing deals for its pipelines. The company has secured four pipeline out-licensing agreements with Fosun Pharma, Exelixis, and Menarini, collectively valued at over $2.1 billion. Concurrently, Insilico has initiated multiple drug discovery and development collaborations with industry partners, including Sanofi, Saudi Aramco, Therasid Bioscience and others, with the collected value of over $1.4 billion. Many of these partnerships have reached milestones, resulting in milestone payments to Insilico, further contributing to the company's growing financial performance. With the successful completion of its Series E financing, Insilico will further accelerate the advancement of AI-powered biopharmaceutical research and development, strengthen collaboration across the industry value chain, and drive the application of its cutting-edge AI platform in diverse scenarios within the life sciences sector through flagship use cases. About Insilico Medicine Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. For more information, please visit www.insilico.com. About Value Partners Group Limited Value Partners, one of Asia's leading independent asset management firms, seeks to offer world-class investment services and products. Since its establishment in 1993, the Company has been a dedicated, specialist value investor in Greater China and Asia. In November 2007, Value Partners Group became the first asset management firm to be listed on the Main Board of the Hong Kong Stock Exchange (Stock code: 806 HK). In addition to its Hong Kong headquarters, the firm operates in Shanghai, Shenzhen, Singapore and London. Value Partners' investment strategies cover equities, fixed income, multi-asset, alternatives, real estate and quantitative investment solutions, for institutional and individual clients in Asia Pacific, Europe and the United States. For more information, please visit www.valuepartners-group.com.
HONG KONG, March 13, 2025 /PRNewswire/ -- Kerry Logistics Network Limited ('KLN'; Stock Code 0636.HK), through its subsidiary, Kerry Pharma, and Teva Pharmaceutical Hong Kong Limited ('Teva') entered into an exclusive agreement for fourth-party logistics (4PL) distribution services in Hong Kong, Macau and other markets in the Greater Bay Area. As the sole distributor of the complete range of Teva's products, Kerry Pharma manages Teva's supply chains with end-to-end pharmaceutical logistics solutions, ensuring seamless distribution and stable product availability at all times. The collaboration serves to strengthen KLN's position and deepen its foothold in the pharmaceutical logistics sector, which is essential to public health, while enabling Teva to focus on its core business with strengthened logistics support, enhanced operational efficiency and swift market responsiveness. KLN's dedicated 4PL fulfilment solutions cover inbound logistics, warehousing, distribution, billing, reporting and exports, managing a portfolio of 190 SKUs and over 3,000 delivery points, from hospital pharmacies, clinics to drug stores and key chain channels. Leveraging its multi-temperature storage capability, KLN maintains strict temperature controls for Teva's general pharmaceuticals and sensitive items, including dangerous drugs, ensuring complete cold chain integrity for all products. For deliveries within the Greater Bay Area, KLN offers ocean freight and air freight, respectively, supported by KLN's cold chain solutions. Samuel Lau, Managing Director - Integrated Logistics Asia of KLN, said, "This exclusive partnership not only underscores KLN's commitment to delivering high-quality services, but also enhances our ability to manage Teva's extensive product range effectively. As the sole distributor of Teva's product range, we also handle the crucial regulatory requirements such as import licenses and liaison with the Department of Health, ensuring hassle-free customer experience for Teva. This exclusivity also enables us to foster a deeper collaboration with Teva, aligning our goals and resources to better serve our customers and respond swiftly to market demands." Theodor Wee, General Manager of Teva Greater China, said, "The stable supply of medicines is crucial to patient health, and Teva is always committed to exploring innovative initiatives to improve patient access to medicines continuously. This collaboration also exemplifies Teva's global 'Pivot to Growth' strategy. In the future, we will accelerate to bring more medicines that will meet the evolving needs of patients. Teva looks forward to partnering with Kerry Pharma to promote medical integration and innovation in the Greater Bay Area, leveraging each other's strengths as a model of cooperation." About Kerry Logistics Network Limited (Stock Code 0636.HK) KLN is an Asia-based, global 3PL with a highly diversified business portfolio and extensive coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics, international freight forwarding (air, ocean, road, rail and multimodal) and e-commerce to industrial project logistics and infrastructure investment. With a global presence across 59 countries and territories, KLN has established a solid foothold in half of the world's emerging markets. Its diverse infrastructure, extensive coverage in international gateways and local expertise span across the Mainland of China, India, Southeast Asia, the CIS, Middle East, LATAM and other locations. KLN generated a revenue of over HK$47.4 billion in 2023. It is listed on the Hong Kong Stock Exchange and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index. About Teva Teva Pharmaceutical Industries Ltd. is a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. If patients have a need, we're already working to address it. Teva China has offices in Shanghai, Beijing, and Hong Kong. Teva China has established strong collaboration with partners across various sectors to enhance the product accessibility and affordability. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Medical/Pharmaceuticals
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
